Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

News: $ORMP Oramed Announces Last Patient Treated in

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 50
Posts 6,479
Boards Moderated 1
Alias Born 06/04/18
160x600 placeholder
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:18:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/5/2019 4:49:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/5/2019 4:42:36 PM
Oramed to Present at Three Upcoming Conferences PR Newswire (US) - 9/3/2019 8:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 5:28:25 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/6/2019 1:29:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 6:08:14 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/19/2019 12:12:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/18/2019 1:32:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/15/2019 7:03:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/10/2019 5:28:14 PM
Oramed to Present at World Diabetes Congress PR Newswire (US) - 7/10/2019 8:40:00 AM
whytestocks Member Level  Tuesday, 09/17/19 02:50:24 PM
Re: None
Post # of 520 
News: $ORMP Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

NEW YORK , Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Ph...

In case you are interested ORMP - Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist